| abstract |
The present invention provides methods and compositions for determining whether a patient with adenocarcinoma or squamous cell carcinoma is capable of responding to treatment of PARP inhibitors. More particularly, the invention relates to a method for evaluating whether a subtype of adenocarcinoma-type lung cancer (AD) of a patient is of the terminal respiratory unit (TRU), proximal inflammatory (PI) or proximal proliferative type. (PP) or if squamous cell carcinoma of the patient (SQ) is primitive, classical, secretory or basal. The method includes detecting levels of classifier biomarkers at the nucleic acid level in a sample of AD or SQ lung cancer taken from the patient. Based in part on the levels of the classifier biomarkers, the lung cancer sample AD is classified as a sample of AD TRU, PI, or PP or the lung cancer sample SQ is classified as primitive, classical, secretory or basal and a determination that the patient is likely to respond to treatment of PARP inhibitors can be performed. |